ImmunityBio (IBRX) is facing a securities lawsuit alleging that the company and Patrick Soon-Shiong overstated what Anktiva could do in promotional statements, including statements that the FDA later deemed false or misleading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmunityBio is facing a securities lawsuit alleging investors were misled about how the company promoted Anktiva, its lead biologic product, before an FDA warning letter dated March 13, 2026, was publicized on March 24, 2026, which described the company’s TV ad and podcast as false or misleading. The complaint says ImmunityBio shares fell 21% on March 24, 2026, after the warning letter became public, and it says the class period ran from January 19, 2026, through March 24, 2026.
Investors who traded ImmunityBio during that period may want to review the allegations and assess whether they were affected.
ImmunityBio and the Anktiva Drug at the Center of the Case
According to the complaint, ImmunityBio is a biotechnology company based in San Diego, California, with laboratories in Culver City and El Segundo. The lawsuit says the case centers on Anktiva, which the complaint identifies as the company’s lead biologic product and the subject of the challenged promotional statements.
The company’s common stock trades on the Nasdaq Global Select Market under the ticker IBRX, according to the complaint. The pleading also says Defendant Patrick Soon-Shiong served as Executive Chairman and Global Chief Scientific and Medical Officer during the relevant period.
What the Complaint Alleges About Anktiva Promotion
The complaint says the case is about whether ImmunityBio and Soon-Shiong overstated Anktiva’s capabilities in promotional statements made during the class period. It alleges that statements in a January 19, 2026, podcast and related promotional materials suggested Anktiva could treat all cancers, prevent cancer after radiation exposure, or function in ways not supported by the drug’s approved uses.
The pleading says those statements were materially false or misleading because they allegedly suggested benefits beyond the data and approval described in the complaint. The overall theme is that investors were allegedly given a more expansive picture of Anktiva’s capabilities than the complaint says the FDA later said was supported.
Readers following the stock’s reaction and the company’s disclosures may want to keep an eye on how the case develops.
What Management Said About Anktiva
The complaint quotes or paraphrases statements made by Soon-Shiong on a January 19, 2026, podcast posted on the company’s website. Among other things, the complaint says he described IL-15 and said Anktiva was “approved for bladder cancer, but it actually can treat all cancers,” called it “the therapy to prevent cancer if you were exposed to radiation,” and referred to it as “a single jab” and “a little vial that you inject subcutaneously.”
The complaint also says Soon-Shiong made remarks that framed Anktiva as a rescue option after checkpoint inhibitors fail and said it was “on the path to curing the cancer.” The pleading ties these statements to the company’s promotional efforts and says they preceded the alleged corrective disclosure.
Corrective Disclosures: FDA Warning Letter and Market Reaction
The complaint says the truth began to emerge on March 24, 2026, when an FDA warning letter dated March 13, 2026, was publicized. According to the complaint, the letter said the FDA had reviewed a TV ad and a podcast about Anktiva, determined that both were false or misleading, and stated that the materials misbranded the drug and suggested uses for which it lacked approval.
The complaint also says Bloomberg published an article on March 24, 2026 titled “ImmunityBio Plunges After Getting FDA Warning on Cancer Drug.” It says the article reported that the company’s shares plunged after the FDA warning letter and noted that the agency took issue with the TV ad and the January podcast in which Soon-Shiong said Anktiva could treat all cancers.
The complaint pleads that ImmunityBio’s common stock fell $1.98 per share, or 21%, to close at $7.42 on March 24, 2026. It treats that move as the stock-price reaction following the alleged corrective disclosure.
Why the Case Matters to IBRX Investors
The complaint’s investor theory is that the market may have priced ImmunityBio shares based on promotional claims about Anktiva that the company allegedly could not support. When the FDA warning letter became public, the complaint says the stock dropped sharply, which the pleading links to investor losses.
For shareholders who bought during the class period, the significance of the case is that it alleges the company’s public messaging about Anktiva may have painted an overly optimistic picture of the drug’s uses and prospects. The complaint says those alleged misstatements and omissions were tied to artificial inflation in the share price before the March 24 drop.
The Securities Claims Asserted in the Complaint
The complaint alleges violations of Section 10(b) of the Securities Exchange Act and Rule 10b-5, as well as Section 20(a) claims against the individual defendant. It says the challenged statements were false or misleading because they allegedly overstated Anktiva’s efficacy, suggested unapproved uses, and omitted facts needed to make the company’s promotional claims not misleading.
The pleading says Soon-Shiong controlled or participated in the challenged statements and that ImmunityBio is responsible for the alleged conduct through agency principles. It also says the company and its executives acted knowingly or recklessly in making or approving the statements described in the complaint.
Investors who believe they were affected may want to learn more about their rights and the allegations in the case.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.